statementSaid on 2026-11-11
LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
其LY03017針對阿爾茨海默病精神病性障礙已在中國進入Ⅱ期臨床並完成首例給藥,LY03020作為全球首個TAAR1/5-HT2CR雙靶點激動劑,同樣將阿爾茨海默病精神病性障礙列為目標適應症。
Discussion
Related claims
The self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.post author · statementCM383 has started Phase Ib clinical trials for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, and some brokerages regard it as a potential leading Aβ antibody in China; CM559 has also advanced to Phase I clinical trials.post author · statementXinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.post author · statementSimcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.post author · statementBased on current experimental data, the targets of the three pipelines are relatively clear and have a certain probability of becoming drugs.昂利康 · statementAfter acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.post author · statement